Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10031664 | 1.00 | MAPK1 (0.50) | MAPK1PKMHTTHCRTR1TDP1 | |
| SCHEMBL10031663 | 0.94 | MAPK1 (0.48) | MAPK1PKMHTTHCRTR1TDP1 | |
| SCHEMBL344101 | 0.94 | MAPK1 (0.48) | MAPK1PKMHTTHCRTR1TDP1 | |
| SCHEMBL345689 | 0.90 | HCRTR1 (0.44) | MAPK1HTTHCRTR1TDP1MEN1 | |
| SCHEMBL344550 | 0.85 | PSEN1 (0.43) | MAPK1HCRTR1TDP1MEN1KMT2A | |
| SCHEMBL12503223 | 0.85 | MAPK1 (0.42) | MAPK1PKMHTTHCRTR1TDP1 | |
| SCHEMBL1696954 | 0.83 | MAPK1 (0.59) | MAPK1PKMHTTMEN1KMT2A | |
| SCHEMBL345185 | 0.83 | THRB (0.45) | HCRTR1TDP1MEN1KMT2ALMNA | |
| SCHEMBL345252 | 0.82 | MAPK1 (0.54) | MAPK1PKMHTTMEN1KMT2A | |
| SCHEMBL344835 | 0.82 | MAPK1 (0.56) | MAPK1PKMHTTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9714238-B2 | Therapeutic agents for ocular hypertension | ALLERGAN, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-20160340347-A9 | THERAPEUTIC AGENTS FOR OCULAR HYPERTENSION | ALLERGAN, INC. (US) | 2016-11-24 | — | — | US | disclosed |
| US-20150175586-A1 | THERAPEUTIC AGENTS FOR OCULAR HYPERTENSION | ALLERGAN, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-8633220-B2 | Therapeutic agents for ocular hypertension | ALLERGAN, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-20120015978-A1 | THERAPEUTIC AGENTS FOR OCULAR HYPERTENSION | ALLERGAN, INC. (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175586-A1 | THERAPEUTIC AGENTS FOR OCULAR HYPERTENSION | PTGIR, NHERF1, PTGS1 | MAPK1 621/4885PKM 3946/4885HTT 1286/4885 |
| US-20160340347-A9 | THERAPEUTIC AGENTS FOR OCULAR HYPERTENSION | PTGIR, NHERF1, PTGS1 | MAPK1 621/4885PKM 3946/4885HTT 1286/4885 |
| US-20120015978-A1 | THERAPEUTIC AGENTS FOR OCULAR HYPERTENSION | PTGIR, NHERF1, PTGS1 | MAPK1 621/4885PKM 3946/4885HTT 1286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.